The Percept™ family with BrainSense™ technology† is the only sensing-enabled DBS system offering insights into a patient’s condition inside and outside of the clinic throughout the patient journey.
How it works
BrainSense™ technology captures brain signals (local field potentials or LFPs) using the implanted DBS lead. These signals can be recorded simultaneously while delivering therapeutic stimulation, inside and outside the clinic. Clinicians can also correlate these brain signals with stimulation and patient-captured events such as medication, symptoms, or side effects.
See how BrainSense™ technology captures brain signals at the exact time a person with Parkinson’s disease experiences symptoms even when symptoms occur outside of an office visit. (This is an animated example representing a person with Parkinson’s disease.)
Now with cutting-edge advancements exclusive to the Medtronic Percept™ family of devices for Parkinson’s disease
BrainSense™ Electrode Identifier
The BrainSense ™ Electrode Identifier feature guides you to the sensing “sweet spot” on the lead, providing a starting point for DBS programming and identification of initial contacts for stimulation delivery.
BrainSense™ Adaptive DBS (aDBS)
aDBS uses BrainSense™ technology to automatically adjust therapeutic stimulation to maximize motor symptom control throughout the day and night.‡
BrainSense™ Electrode Identifier for Parkinson’s disease
Electrode identifier guides you to the sensing "sweet spot" on the lead
Select an initial contact in <2 minutes§,1
New BrainSense™ aDBS for Parkinson’s disease
aDBS offers improved motor symptom control, on average, with BrainSense™ aDBS compared to cDBS.‡
aDBS uses BrainSense™ technology to automatically adjust therapeutic stimulation to maximize motor symptom (rigidity, bradykinesia, tremor) control throughout the day and night.‡
Safety
There are risks and benefits of DBS: Risks include surgical complications, infection, failure to deliver therapy as needed and/or worsening of some symptoms.
The safety profile observed for aDBS is consistent with the safety profile for cDBS. Stimulation-related side effects are expected during initial aDBS setup, such as worsening of Parkinson’s disease symptoms and dyskinesias, and are expected to resolve with reprogramming. It’s important to ensure patients have regular follow up visits to monitor response to therapy, optimize programming, and manage any stimulation-related side effects promptly, especially within aDBS adjustment and set up periods (at least within the first few months of aDBS programming). aDBS is an optional programming feature and may not work for everyone.
Medtronic’s DBS therapy is approved for five indications: Parkinson’s disease, essential tremor, dystonia, obsessive-compulsive disorder (OCD), and epilepsy. Indications vary by product, refer to product labeling for details.
Humanitarian device: The effectiveness of these devices for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated.
† The sensing feature of the Percept™ PC system and Percept™ RC system is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status. The majority of patients with Parkinson’s disease have an identifiable signal. Signal may not be present or measurable in patients treated for essential tremor, dystonia, epilepsy or obsessive-compulsive disorder. Humanitarian device: The effectiveness of these devices for the treatment of dystonia or obsessive-compulsive disorder has not been demonstrated.
‡ Improved motor symptom control results were based on post hoc analysis averaging overall patient aDBS on time results compared to cDBS. Results presented for dual threshold aDBS. N=40. Based on results from an open-label comparison.
§ At initial programming, compared to standard monopolar review for Parkinson's disease.
◊ Medtronic DBS systems are MR Conditional. Refer to product labeling for full list of conditions.
Data on file, Medtronic. Results based on bench testing, may not be indicative of clinical experience.
Electrode identifier guides you to the sensing "sweet spot" on the lead
Select an initial contact in <2 minutes§,1
